Analysts expect DexCom, Inc. (NASDAQ:DXCM) to post sales of $211.91 million for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for DexCom’s earnings, with estimates ranging from $198.00 million to $215.80 million. DexCom reported sales of $171.20 million in the same quarter last year, which indicates a positive year-over-year growth rate of 23.8%. The company is scheduled to report its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that DexCom will report full-year sales of $211.91 million for the current year, with estimates ranging from $695.40 million to $725.00 million. For the next year, analysts expect that the business will post sales of $857.21 million per share, with estimates ranging from $820.60 million to $918.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover DexCom.
Several equities research analysts have recently issued reports on the company. BMO Capital Markets raised their target price on DexCom to $74.00 and gave the company an “outperform” rating in a research report on Tuesday. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research report on Monday, November 6th. Morgan Stanley decreased their target price on DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Finally, Barclays decreased their target price on DexCom from $60.00 to $57.00 and set an “equal weight” rating for the company in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $71.36.
In other news, EVP Andrew K. Balo sold 6,490 shares of the stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total transaction of $389,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The disclosure for this sale can be found here. Insiders have sold a total of 34,710 shares of company stock valued at $2,031,852 in the last quarter. 1.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC boosted its stake in DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after purchasing an additional 978,898 shares during the period. Janus Henderson Group PLC boosted its stake in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after purchasing an additional 1,991,094 shares during the period. Vanguard Group Inc. boosted its stake in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after purchasing an additional 224,808 shares during the period. BlackRock Inc. boosted its stake in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after purchasing an additional 230,542 shares during the period. Finally, Brown Advisory Inc. boosted its stake in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after purchasing an additional 1,515,134 shares during the period.
Shares of DexCom (NASDAQ:DXCM) opened at $57.25 on Wednesday. DexCom has a 12-month low of $42.62 and a 12-month high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.
WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/13/211-91-million-in-sales-expected-for-dexcom-inc-dxcm-this-quarter.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Get a free copy of the Zacks research report on DexCom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.